Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients
The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.
Leukemia|Hodgkin Disease|Non-Hodgkin Lymphoma|Myelodysplastic Syndrome|Multiple Myeloma
Donor T-cell chimerism, Day 28 post-transplant
Exposure to cyclophosphamide, fludarabine, and mycophenolate mofetil and their breakdown products, 1 week before through 3 weeks after transplant
The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.